Retatrutide
Retatrutide is an investigational synthetic peptide designed to activate three hormone pathways involved in appetite, blood sugar, digestion, and energy use. Researchers are studying whether this combined activity may support weight management and other areas of metabolic health.
RETATRUTIDE AT A GLANCE
WHAT IS RETATRUTIDE?
Retatrutide is a laboratory-made peptide designed to copy the activity of three hormones involved in the body’s response to food. These hormones are GIP, GLP-1, and glucagon. Each communicates with different tissues involved in appetite, blood sugar, digestion, and energy use.
By combining all three activities into one compound, researchers hope to influence several connected parts of metabolism at the same time. Retatrutide is sometimes called a triple-hormone-receptor agonist or triple agonist for this reason.
HOW DOES RETATRUTIDE WORK?
Retatrutide activates GIP and GLP-1 receptors, which help the body release insulin when blood sugar rises. GLP-1 activity can also slow digestion and strengthen signals of fullness between the digestive system and brain, potentially reducing hunger and food intake.
The third pathway involves glucagon. Although glucagon can increase the release of stored sugar, it may also affect how the body uses stored energy and processes fat in the liver. Researchers are investigating whether carefully balancing these three signals can support blood sugar control while producing broader effects on appetite, body weight, and metabolism.
Areas of Research
Retatrutide research examines whether three connected hormone pathways can work together to influence weight, blood sugar, energy use, and obesity-related health concerns.
APPETITE AND BODY WEIGHT
Studying hunger, fullness, food intake, body weight, and whether changes can be maintained over longer periods.
BLOOD SUGAR CONTROL
Examining insulin release, long-term blood sugar measurements, and the body’s response to insulin in people with type 2 diabetes.
ENERGY USE AND FAT METABOLISM
Exploring whether glucagon-receptor activity changes energy expenditure, fat use, or the way the liver processes stored nutrients.
OBESITY-RELATED CONDITIONS
Investigating retatrutide in connection with sleep apnea, knee osteoarthritis, fatty liver disease, heart health, and other conditions associated with obesity.
Research Highlights
A Phase 2 trial involving adults with obesity found dose-dependent reductions in body weight over 48 weeks. A separate Phase 2 study involving people with type 2 diabetes reported improvements in blood sugar control and body weight. Digestive reactions—including nausea, diarrhea, vomiting, and constipation—were among the most commonly reported side effects, particularly as doses increased.
Phase 3 studies have since examined retatrutide in larger groups of adults with obesity, type 2 diabetes, sleep apnea, knee osteoarthritis, and cardiovascular disease. Several studies have reported positive results, but some findings have only been released as company summaries and have not yet undergone complete peer-reviewed publication. Retatrutide remains investigational while additional studies and the regulatory review process continue.
WHAT IS RETATRUTIDE MOST COMMONLY RESEARCHED FOR?
Retatrutide is most commonly researched for obesity, long-term weight management, and type 2 diabetes. Researchers examine how it affects appetite, food intake, body weight, insulin response, and blood sugar over time. Its possible effects on liver fat, sleep apnea, joint discomfort, and cardiovascular risk are also being studied because these concerns frequently overlap with obesity and metabolic disease.
HOW DOES RETATRUTIDE FIT INTO PEPTIDE RESEARCH?
Retatrutide represents a growing area of research involving peptides that activate several biological pathways at once. Earlier compounds focused on GLP-1 alone, while later research combined GLP-1 with GIP. Retatrutide adds glucagon-receptor activity, allowing researchers to investigate whether three coordinated signals can produce broader metabolic effects than a single- or dual-pathway peptide.
WHAT MAKES RETATRUTIDE UNIQUE?
Retatrutide stands out because it activates GIP, GLP-1, and glucagon receptors within a single peptide. GIP and GLP-1 contribute to insulin release and appetite regulation, while glucagon may influence energy expenditure and fat metabolism. The challenge for researchers is determining whether these activities can be balanced in a way that produces meaningful benefits without creating unacceptable side effects or blood sugar changes.
HOW IS RETATRUTIDE DIFFERENT FROM TIRZEPATIDE?
Tirzepatide activates two hormone pathways—GIP and GLP-1—while retatrutide activates GIP, GLP-1, and glucagon receptors. The added glucagon activity may affect energy expenditure and the use of stored fat, but it also makes retatrutide’s activity more complex. Tirzepatide is available in FDA-approved medications for specific uses, while retatrutide remains investigational and is not approved for public use.
WHAT HAVE RESEARCHERS LEARNED ABOUT RETATRUTIDE SO FAR?
Researchers have learned that retatrutide can produce substantial changes in body weight and blood sugar among many clinical-trial participants. Studies have also reported changes in waist size, blood pressure, cholesterol, liver fat, and other metabolic measurements. Digestive side effects have been common, and increases in heart rate, changes in skin sensation, and other reactions have also been monitored. Longer studies are still needed to clarify its safety, durability, and effects on major health outcomes.
IS RESEARCH ON RETATRUTIDE CONTINUING TODAY?
Yes. Phase 3 research continues to examine retatrutide across obesity, type 2 diabetes, cardiovascular disease, kidney disease, sleep apnea, osteoarthritis, and other metabolic conditions. Researchers are also comparing it directly with tirzepatide and evaluating different dose-escalation approaches. Lilly has announced plans to begin seeking regulatory approval in 2027, but approval is not guaranteed and retatrutide remains unavailable as an FDA-approved medication.